A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study of Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and the Controlled Adverse Environmental (CAE) Model for the Treatment of Dry Eye Syndrome
Latest Information Update: 03 May 2022
At a glance
- Drugs Plastoquinonyl-decyl-triphenylphosphonium (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms VISTA-2
- Sponsors Mitotech
Most Recent Events
- 28 Apr 2022 According to a Ora Inc media release, data from VISTA-1 and VISTA-2 studies will be presented at the Association for Research in Ophthalmology Conference (ARVO), 2022.
- 20 Dec 2021 Status changed from active, no longer recruiting to completed.
- 26 Feb 2021 Results presented in a Mitotech media release.